The frequency of this haplotype is around 45% in the general population and its presence has been associated to an increased risk of MPN onset, preferentially—but not exclusively—carrying JAK2 driver mutations (including V617F exon 14 mutation and exon 12 mutations). The gene discussed is JAK2; the disease is myeloproliferative neoplasm.